Intra-articular 2.5% polyacrylamide hydrogel, a new concept in the medication of equine osteoarthritis: A review.
Authors: Tnibar Aziz
Journal: Journal of equine veterinary science
Summary
# Intra-articular 2.5% Polyacrylamide Hydrogel for Equine Osteoarthritis: Editorial Summary Intra-articular polyacrylamide hydrogel (PAAG) at 2.5% concentration represents a novel approach to managing equine osteoarthritis, distinct from conventional treatments in both mechanism and durability. This review synthesised clinical and experimental evidence demonstrating that PAAG achieves 82.5% lameness-free status at two-year follow-up—a longevity of effect unmatched by other single osteoarthritic medications currently available. Rather than modulating inflammatory pathways, PAAG appears to work through mechanical integration into the synovial membrane, sustained viscosupplementation, and restoration of joint capsule elasticity, thereby reducing degenerative stress on articular cartilage surfaces. Importantly, the available literature indicates no neurotoxic or fibrotic complications, though the authors acknowledge methodological limitations across existing studies. For equine practitioners, PAAG offers a promising long-acting option warranting consideration in cases where conventional intra-articular therapies have proven insufficient, though further rigorous, standardised trials would strengthen the evidence base and clarify optimal candidate selection criteria.
Read the full abstract on PubMed
Practical Takeaways
- •2.5% PAAG offers a long-acting injectable alternative for managing OA in lame horses, with over 80% remaining sound at 2-year follow-up
- •This treatment works through physical integration and joint protection rather than anti-inflammatory mechanisms, representing a different approach to conventional intra-articular medications
- •Safety profile appears excellent with no reported neurotoxicity or fibrosis, making it suitable for performance horses where joint integrity is critical
Key Findings
- •Intra-articular 2.5% PAAG achieved 82.5% lameness-free rate at 2-year follow-up in treated horses
- •Mechanism of action involves mechanical integration into synovial membrane and lasting viscosupplementation without pro-inflammatory cytokine effects
- •No observed intra-articular neurotoxicity or fibrosis associated with 2.5% PAAG treatment
- •PAAG demonstrates prolonged efficacy superior to other single medical treatments for equine osteoarthritis